BioNTech (BNTX) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed BioNTech (BNTX) over the past year, gaining 304.8% versus a loss of 7.2%. Over five years, SYRE leads with a -58.1% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $8.01 billion), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | SYRE |
|---|---|---|
| Share price | $96.96 | $85.69 |
| Market cap | $24.36B | $8.01B |
| 1-day change | +5.32% | +7.25% |
| YTD return | +1.85% | +161.57% |
| 1-year return | -7.20% | +304.77% |
| 5-year return | -60.85% | -58.10% |
| EPS (TTM) | $-7.83 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-155.20M |
| 52-week high | $124.00 | $110.18 |
| 52-week low | $79.52 | $18.12 |
| Distance from 52-week high | -21.81% | -22.22% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.85% | +40.28% |
| Average volume | 1.17M | 1.22M |
| Shares outstanding | 251.20M | 93.45M |
| Employees | 7,807 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 3.0 times larger than Spyre Therapeutics by market value ($24.36B vs $8.01B).
- SYRE has outperformed BNTX by 312.0 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
BNTX vs SYRE FAQ
Which is bigger, BioNTech or Spyre Therapeutics?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $8.01B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, BNTX or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -7.20% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Spyre Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Spyre Therapeutics.